Skip to search formSkip to main contentSkip to account menu

Delavirdine

Known as: Delavirdin, 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine, Delavirdina 
A synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs, this agent has been shown to reduce HIV… 
National Institutes of Health

Related topics

Related topics

29 relations
Acquired Immunodeficiency SyndromeAlprazolamAstemizoleCisapride

Broader (5)

Anti-HIV AgentsAntiviral AgentsIndolesPiperazines

Narrower (2)

RescriptorU-90152

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Alkoxyphenyl methanesulfonamides: synthesis, anti-inflammatory effect, and docking studies
A series of 2-alkoxyphenyl methanesulfonamide-based compounds were synthesised and evaluated for their anti-inflammatory activity… 
2011
2011
Pharmaceutical compositions (r) -1- (2, 2-difluorobenzo [d] [1, 3] dioxol-5-yl) -n- (2, 3-dihydroxypropyl) -6-fluoro-2- (1-hydroxy- 2-methylpropan-2-yl) -1H-indol-5-yl) cyclopropanecarboxamide and…
1. A tablet for oral administration comprising: a. Compound 1; b. filler; s.razbavitel; d. disintegrant; e. lubricant and f… 
2000
2000
Amprenavir is an effective inducer of delavirdine metabolism - A Steady-State Pharmacokinetic Interaction Study Between Amprenavir and Delavirdine in Healthy Volunteers
Background: Amprenavir (APV) and delavirdine (DLV) are both primarily metabolized by cytochrome P450 (CYP) 3A4. The pill burden… 
2000
2000
INTERACTION OF DELAVIRDINE WITH HUMAN LIVER MICROSOMAL CYTOCHROME P 450 : INHIBITION OF CYP 2 C 9 , CYP 2 C 19 , AND CYP 2 D 6
Delavirdine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, is metabolized primarily through desalkylation catalyzed… 
Review
1999
Review
1999
Pharmacology of antiretroviral drugs.
Abstract In this paper, an overview of the pharmacokinetics of currently available antiretroviral drugs is provided. Included in… 
1997
1997
Delavirdine (Rescriptor) approved.
The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) for HIV-1 treatment in March. Delavirdine becomes the… 
1997
1997
Delavirdine levels in women.
Results from a clinical trial of 718 participants, 139 of them women, indicate that women experience 1.8 times higher… 
1997
1997
Delavirdine gets FDA approval. Food and Drug Administration.
Delavirdine (Rescriptor), a non-nucleoside reverse transcriptase inhibitor, has received Food and Drug Administration (FDA… 
1997
1997
DMP 266 trials recruiting, many cities -- protease inhibitor naive.
1996
1996
Delavirdine/protease inhibitor interactions.
On September 27, 1996, the Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee meets to consider licensing…